Helixgate

Helixgate

Uncategorized

STAT+: Large AI scribe study finds modest time savings, inconsistent use

Published

on

Ambient scribes were supposed to ease the burden on stressed-out doctors by automating clinical documentation from patient visits. A new study highlights the need to help clinicians make the best use of the tools.

The large new study of AI scribe use by 1,800 clinicians across five academic medical centers from 2023 to 2025 found those using the technology saved 16 minutes of documentation time and spent 13 fewer minutes in the medical record for every eight hours of patient care. The study did not find significant impacts on time spent in the electronic health record outside of work. Primary care and female clinicians benefitted more than others. Scribe adopters were able to see one additional patient every two weeks.

The findings offer the most definitive real-world data confirming earlier smaller studies. A STAT review of published work last year found scribes saved clinicians under a minute per clinical note. Surprisingly, despite the modest time savings, other studies have found that scribes drive large improvements in burnout and other measures of clinician well-being. 

Continue to STAT+ to read the full story…

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

BioNTech to shutter Singapore HQ after ‘comprehensive review’   

Published

on

BioNTech, in a move to streamline its operations, is set to close its factory in Singapore that it bought from Novartis just over three years ago.

The facility at the Tuas Biomedical Park, which employs …

Continue Reading

Uncategorized

STAT+: Merck’s experimental HIV prevention pill could be made for less than $5 a year, researchers say

An experimental HIV prevention pill being developed by Merck could be mass produced for less than $5 per patient a year according to a new analysis. Advocates argue the low cost means the company should find it easier to license the drug so that low- and middle-income countries can gain easy access.

The pill, dubbed MK 8527, is currently undergoing a pair of late-stage clinical trials that are expected to determine whether the medicine can lower HIV transmission when given to people at high risk of infection. The results are due in the latter half of 2027, according to ClinicalTrials.gov.

Already, the pill is generating considerable interest after Merck released mid-stage results last summer showing its drug holds promise. In addition to being safe and effective, the study found it could protect against infection, a form of prevention known as pre-exposure prophylaxis or PrEP, within 24 hours after being taken. Merck noted the pill works in a novel way.

Continue to STAT+ to read the full story…

Read More

Published

on

An experimental HIV prevention pill being developed by Merck could be mass produced for less than $5 per patient a year according to a new analysis. Advocates argue the low cost means the company should find it easier to license the drug so that low- and middle-income countries can gain easy access.

The pill, dubbed MK 8527, is currently undergoing a pair of late-stage clinical trials that are expected to determine whether the medicine can lower HIV transmission when given to people at high risk of infection. The results are due in the latter half of 2027, according to ClinicalTrials.gov.

Already, the pill is generating considerable interest after Merck released mid-stage results last summer showing its drug holds promise. In addition to being safe and effective, the study found it could protect against infection, a form of prevention known as pre-exposure prophylaxis or PrEP, within 24 hours after being taken. Merck noted the pill works in a novel way.

Continue to STAT+ to read the full story…

Read More

Continue Reading

Uncategorized

Opinion: STAT+: Former Geisinger CEO: U.S. health systems must replace huge numbers of people with AI 

About 20 years ago, I stepped on stage at one of our Geisinger town halls and looked out upon a sea of people: thousands of full-time employees at an integrated health system charged with the health and well-being of millions of Pennsylvanians. 

Only a fraction of the people in that room were clinicians. 

That was the first time I fully visualized the problem: We employed more people in our revenue cycle department to process bills and reconcile data than we did doctors. And we weren’t alone. It’s the same story at every health system in America, large and small, and over the past two decades, the ratio has become dramatically more disparate. 

Continue to STAT+ to read the full story…

Read More

Published

on

About 20 years ago, I stepped on stage at one of our Geisinger town halls and looked out upon a sea of people: thousands of full-time employees at an integrated health system charged with the health and well-being of millions of Pennsylvanians. 

Only a fraction of the people in that room were clinicians. 

That was the first time I fully visualized the problem: We employed more people in our revenue cycle department to process bills and reconcile data than we did doctors. And we weren’t alone. It’s the same story at every health system in America, large and small, and over the past two decades, the ratio has become dramatically more disparate. 

Continue to STAT+ to read the full story…

Read More

Continue Reading
Advertisement

Trending